CDK6 and acute lymphoblastic leukemia: De Dominici et al. showed promising first results using CDK6 degrader in vivo; xenotransplanted mice with patient-derived Philadelphia-positive ALL cells had drastically reduced leukemia burden due to CDK6 degrader treatment [104].